A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This open-label, multi-center study will evaluate the safety, tolerability and effect of
bevacizumab (Avastin) in combination with taxane (paclitaxel/ docetaxel) monotherapy on
disease progression, survival time and Karnofsky performance status in female participants
with estrogen-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative
(triple-negative) breast cancer.